AHK-Cu

Think of it as a promising audition rather than a finished film. AHK-Cu performed well in the lab 'rehearsal room' (cells in a dish, follicles in a jar), but it has never been cast in a real human trial. Brands sell tickets as if the movie already won awards.

A small peptide (alanine-histidine-lysine) that chelates copper(II) and acts as a copper carrier, delivering copper to copper-dependent enzymes involved in collagen cross-linking and matrix remodelling. In cell culture it was associated with increased VEGF (pro-angiogenic) and suppressed TGF-beta1, plus increased dermal papilla cell proliferation, proposed to prolong the follicle growth (anagen) phase. Applied topically in cosmetics. Laboratory effects appeared only at very low concentrations.

Research contexts. Not proven uses, and not recommendations.

None specific to AHK-Cu. No published controlled clinical trials demonstrate that AHK-Cu grows hair, reduces hair loss, or improves skin ageing in humans. The main evidence is a single 2007 study using cultured human dermal papilla cells and isolated human hair follicles in organ culture. Its presence in cosmetics relies on mechanistic data and borrowing from the broader cosmetic experience with GHK-Cu. Claims of proven human results for AHK-Cu itself overstate the evidence.

• !No human efficacy trials: marketing claims for hair regrowth and anti-ageing lack clinical data specific to AHK-Cu.
• !Read-across overreach: benefits are often borrowed from GHK-Cu studies, a different molecule.
• !Concentration-dependent effects: lab data showed stimulation only at very low concentrations, so 'more is better' marketing is mechanistically questionable.
• !Grey-market quality: many products are sold as unlicensed 'research chemicals' with no verified purity, copper content, sterility, or peptide identity testing.
• !Copper exposure: copper can be irritating or sensitising to skin in some formulations; injectable/grey-market use carries sterility and contamination risks.
• !Regulatory ambiguity: legitimate as a topical cosmetic, but products promising therapeutic hair-loss outcomes make unlicensed medicinal claims.

AHK-Cu (Copper Tripeptide-3) is recognised as a cosmetic ingredient (INCI-listed) and may be used in topical cosmetic products in the UK if they are safety-assessed and make only cosmetic (not medicinal) claims under the UK Cosmetics Regulation, enforced by the Office for Product Safety and Standards (OPSS) and local Trading Standards. It is not a licensed UK medicine and holds no MHRA marketing authorisation for hair loss, skin ageing, or any therapeutic use. Any product marketed as treating, preventing, or curing a condition (such as claiming to regrow hair in androgenetic alopecia) makes a medicinal claim and would require MHRA authorisation under the Human Medicines Regulations 2012, which it does not have. Peptide powders or vials sold for reconstitution and injection with labels such as 'research use only' or 'not for human consumption' are unlicensed and outside any approved medical use. Selling or supplying them for human use is unlawful.

1. 01
   The effect of tripeptide-copper complex on human hair growth in vitro — Pyo HK, Yoo HG, Won CH, et al., Archives of Pharmacal Research 2007;30(7):834-839 (2007)

   The cornerstone ex-vivo/in-vitro study: AHK-Cu (10^-12 to 10^-9 M) promoted human hair follicle elongation ex vivo and dermal papilla cell proliferation in vitro, with associated VEGF upregulation and TGF-beta1 suppression. The anti-apoptotic shift did not reach statistical significance. No human clinical outcomes.

2. 02
   GHK and DNA: Resetting the Human Genome to Health (review of copper-peptide GHK-Cu biology) — Pickart L, Margolina A, International Journal of Molecular Sciences (2018)

   Major review of the related copper tripeptide GHK-Cu; relevant as the basis for most read-across claims applied to AHK-Cu. Note this is GHK-Cu, NOT AHK-Cu.

3. 03
   Copper, lysyl oxidase and collagen cross-linking in skin and connective tissue (background literature), Dermatology / trace-element literature (2015)

   Background on copper's role in lysyl-oxidase-mediated collagen cross-linking, supporting the proposed mechanism of copper-delivery peptides. General, not AHK-Cu specific; descriptive search link provided rather than a single identifier.